Ultimovacs Announces Completion of Patient Enrollment in Supplementary Study to INITIUM, UV1 Phase II Trial in Malignant Melanoma

  The supplementary study to INITIUM is designed to provide in-depth data on the biological activity and mode of action of the vaccine-induced T cells, to support the next stages of...

Related Keywords

Norway ,Oslo ,Belgium ,Germany ,Bristol Myers Squibb ,Halle University ,Astrazeneca ,Euronext Oslo Stock Exchange ,Oslo University Hospital ,Chief Medical Officer ,Human Leukocyte Antigen ,Markets ,